Wendy Yarno elected Chairwomen of Aratana Therapeutics
Aratana Therapeutics, a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that the Board of Directors has elected Wendy Yarno as Chairman of Aratana’s Board of Directors. She will … Continue reading
Genmab and Novo Nordisk in bispecific antibody deal
Genmab A/S (OMX: GEN) announced it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease … Continue reading
Editas adds CFO and $120m in Series B round
Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the … Continue reading
Oxford Nanopore Technologies raises £70m
Oxford Nanopore Technologies Ltd, the UK-based technology company that has designed and produced the world’s first DNA sequencer based on nanopore sensing, making it commercially available in 2014, has raised £70 million ($109 million) in new funding through a private … Continue reading
Jeremy Levin hauls in $75m Series B for Ovid
Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today that it has completed a Series B financing totaling $75 million. Fidelity Management and Research Company led … Continue reading
Dimension Therapeutics Diversifies Leadership with Management and Board Appointment
Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. … Continue reading
Cortendo joins a rare disease crowd in Ireland
Sweden’s Cortendo AB has announced its intention to relocate the parent company of the Cortendo group from Sweden to Ireland. The Company is contemplating effecting such redomiciliation through an exchange offer in which Cortendo plc, a newly incorporated Irish … Continue reading
Shire goes hostile on Baxter spin-out Baxalta
Fresh from announcing that the company will acquire Foresight BioTherapeutics for $300m (here), Shire stepped up its ambitions to acquire the recently spun-out Baxalta, which went public earlier this summer (here). Shire originally approached the Baxalta Board of Directors earlier … Continue reading
BrainStorm recruits new CFO
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate … Continue reading